The diethylstilbestrol (DES) metabolite (8-dienestrol), which had been identified in mouse, rat, monkey, and human urine, and two proposed metabolic intermediates (diethylstilbestrol a,a'-epqxide and a,a'-dihydroxy DES) were synthesized and their estrogenic activities determined. In addition, three DES analogs, a-dienestrol, DES-dihydroxy diethyl phenanthrene (DES-phenanthrene), and 14a-ethyl, 4a-hydroxyphenyl)indanyl-5-ol (indanyl-DES), were studied. Estrogenic activities of the compounds in vivo were determined by the immature mouse uterine weight bioassay; in vitro, their estradiol receptor binding activity (competitive equilibrium binding, sucrose gradient analysis, and association rate inhibition assays) was determined. Results of the mouse uterine weight bioassay gave the following order of estrogenicity: DES > a-dienestrol Diethylstilbestrol (DES) is a nonsteroidal estrogen first synthesized and described by Dodds in 1938 (1). It has significant oral activity as an estrogenic substance and invokes a strong hormonal response equivalent to an injected dose of the steroidal estradiol-17fl.
mately 0.5-19.1 X 1010 M-'), while DES-phenanthrene had the lowest (Ka = 3.5 X 107 M-' + 1.2). Sucrose gradient analysis of the above competition preparations illustrated the displacement of [3H]estradiol from the receptor peak. This displacement was receptor specific and concentration dependent and correlated with the equilibrium binding concentrations. In addition, the most hormonally active substances demonstrated the greatest rate inhibition in the estradiol cytosol receptor association rate reaction (V0). The rank order of estrogenicity of the compounds determined in this study should be useful in evaluating alternative metabolic pathways of DES as well as distinguishing biologically active metabolites from relatively inactive ones.
Diethylstilbestrol (DES) is a nonsteroidal estrogen first synthesized and described by Dodds in 1938 (1) . It has significant oral activity as an estrogenic substance and invokes a strong hormonal response equivalent to an injected dose of the steroidal estradiol-17fl.
In recent years, reports by Herbst and colleagues (2) have linked in utero exposure to DES with subsequent developmernt of vaginal clear cell adenocarcinoma in a number of female offspring. A detailed review by Gunning of the human studies has been published (3). Investigations in our laboratory (4, 5) have been concerned with the development of an animal model system for studying this effect of in utero exposure.
Pharmacokinetic studies with radiolabeled DES in the laboratory mouse model (6) (13) and the results were analyzed according to Korenman (14) .
RESULTS
Competition equilibrium binding experiments for the estradiol cytosol receptor gave a series of sigmoidal competition curves that varied according to the strength of the interaction. From these data apparent equilibrium affinity constants (Ka) could be calculated (13) Then 0.5 nmol of [3H]estradiol was added to start the reaction and the procedure followed was as described (13) .
as indexes of in vivo estrogenicity and are also presented in (Fig. 1A) . The sedimentation properties (approximately 6 S) of the receptor were not altered by the presence of different DES analogs in the preparation. Other studies gave a dose-response of cytoplasmic receptor binding with a proportional drop in the size of the receptor peak as a function of increasing concentrations of competitor.
To further show that these competitors were interacting with the receptor, we analyzed the effect of these compounds on the association rate reaction of estradiol and the cytoplasmic receptor. Data demonstrating the effect of certain competitors on the association rate plot are shown in Fig. 1B . DES or adienestrol gave no association rate since these compounds had competed for the receptor binding sites. Experiments with estradiol-17f3 gave similar results. f-Dienestrol had some effect at this concentration but it was not as dramatic as that of the DES or a-dienestrol samples. DES-phenanthrene was not effective at all. Other experiments, not shown, demonstrated that the effect of the compounds on the reaction is dose dependent and that there is a proportional decrease in the rate as the concentration of competitor is increased.
DISCUSSION
The above data clearly show that some DES metabolites and analogs are estrogenic. Results from the mouse uterine cytoplasmic receptor binding show that this estrogenic activity is due to their ability to interact with the receptor. The equilibrium binding assay does not determine whether the compounds interact with the receptor in a competitive or noncompetitive manner. Those compounds that were checked by the second binding analysis (Lineweaver- (19) . Those compounds that bind the cytoplasmic receptor poorly will not be able to generate an effective nuclear receptor complex, which is derived from the cytoplasmic receptor and requires hormone binding (19) .
Conversely, if a compound adequately interacted with the cytoplasmic receptor but was inadequately translocated to the nucleus, there would be a submaximal biological response. Indanyl-DES may be an example of such a compound since its biological activity is significantly less than predicted from its relatively high affinity for the estradiol receptor. Preliminary studies of the translocation process (K. S. Korach et al., unpublished data) suggest that indanyl-DES does not retain the complex in the nucleus as long as DES.
DES-phenanthrene arises from photocyclization of cis-DES (20) . This process is not unlike that seen for vitamin D3 produced by UV irradiation in the skin from relatively inactive 7-dehydrocholesterol (21) . Consequently, topically applied estrogenic materials (e.g., beauty creams) could become photoactivated. The possibility that this process may cause or increase certain types of cancer is now under study. However, the low estrogenicity of DES-phenanthrene suggests that estrogen-responsive tissues would not represent the major targets for this compound.
DES metabolism may proceed via two routes. One route could produce hormonally inactive metabolites such as fl-dienestrol. The other pathway could produce compounds such as DES-epoxide, which still retain a considerable amount of estrogenic activity. Evidence for such a bilateral metabolism of certain substances has been documented (22) . If DES undergoes such metabolism, then large doses or repeated ingestion could produce compounds in the body that are hormonally active and/or carcinogenic. This study has only attempted to determine the hormonal activity of these compounds and does not concern their carcinogenic properties.
